Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Amwell® Announces Results for Third Quarter 2025
-
Weyco Group, Inc. Declares Special Cash Dividend
-
InnovAge Announces Financial Results for the Fiscal First Quarter Ended September 30, 2025
-
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025
-
Nasdaq Reports October 2025 Volumes
-
Workhorse Group Recommends Shareholders Follow Recommendations of Leading Independent Proxy Advisory Firms to Vote FOR Motiv Transaction Today
-
OrthoPediatrics to Participate in Upcoming Conferences
-
Comscore Reports Third Quarter 2025 Results
-
Kratos to Acquire Israel-Based Orbit Technologies Ltd for $356.3 Million
-
Vaxcyte Reports Third Quarter 2025 Financial Results and Provides Business Update Including Final Data from Positive VAX-24 Infant Phase 2 Dose-Finding Study
-
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)
-
Ceribell Reports Third Quarter 2025 Financial Results
-
Tarsus Reports Third Quarter 2025 Financial Results and Recent Business Achievements
-
Latham Group, Inc. Reports Third Quarter 2025 Financial Results
-
Astera Labs Announces Financial Results for the Third Quarter of Fiscal Year 2025
-
Bitcoin Depot and GPM Investments Partner to Expand Bitcoin Access Across Convenience Stores Nationwide
-
Announcement Regarding Access to the Plan Company’s Evidence Ahead of the Sanction Hearing
-
Cricut, Inc. Reports Third Quarter 2025 Financial Results
-
First Advantage to Participate in Upcoming Investor Conferences
-
Prenetics Announces Third Quarter 2025 Financial Results Release Date and Inaugural Earnings Conference Call
-
Paylocity Announces First Quarter Fiscal Year 2026 Financial Results
-
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
TEN Ltd. Declares Dividend on its Series E Cumulative Perpetual Preferred Shares
-
RAPT Therapeutics to Participate in Multiple Upcoming Investor Conferences
-
LiveRamp to Present at the Wells Fargo 9th Annual TMT Summit
-
Sana Biotechnology to Present at the TD Cowen Immunology & Inflammation Summit
-
Spyre Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
Wildspring by Toll Brothers is Now Open in Leander, Texas
-
Key Tronic Corporation Announces Results for The First Quarter of Fiscal Year 2026
-
PROCEPT BioRobotics Reports Third Quarter 2025 Financial Results and Issues 2026 Revenue Guidance
-
Catalyst Pharmaceuticals Recognized Among BioSpace 2026 Best Places to Work
-
Mulvihill Enhanced Split Preferred Share ETF Declares Monthly Distribution
-
LEEF Brands Reports Third Quarter 2025 Financial Results with Gross Margins More Than Doubling Year-Over-Year
-
Flywire Reports Third Quarter 2025 Financial Results
-
Powell Industries Declares Quarterly Cash Dividend
-
Mulvihill Canadian Bank Enhanced Yield ETF Declares Monthly Distribution
-
Clearway Energy, Inc. Reports Third Quarter 2025 Financial Results
-
Powell Industries Announces Date and Conference Call for Fiscal 2025 Fourth Quarter and Full Year Results
-
Premium Global Income Split Corp. Declares Monthly Distribution
-
Mulvihill Premium Yield Fund Declares Monthly Fund Distribution for its ETF Class
-
Mercury Systems Reports First Quarter Fiscal 2026 Results
-
Premium Income Corporation Announces Monthly Distribution
-
Avadel Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update
-
Cardiff Oncology to Participate in Two Upcoming Investor Conferences
-
Opus Genetics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
-
Corvus Pharmaceuticals Provides Business Update and Reports Third Quarter 2025 Financial Results
-
Soleno Therapeutics Reports Third Quarter 2025 Financial Results and Provides Update on U.S. Launch of VYKAT(TM) XR
-
SLR Investment Corp. Announces Quarter Ended September 30, 2025 Financial Results
-
Ultragenyx Announces Sale of a Portion of Future North American Royalties on Crysvita® (burosumab) for $400 Million to OMERS Life Sciences
-
Supernus Announces Third Quarter 2025 Financial Results

